Increasing patient access to cellular immunotherapy through RNA gene writing

Current CAR-T cell therapies are beset by challenges relating to manufacturing and supply chain cost and complexity, as well as safety and efficacy, all of which limit the number of patients who can potentially benefit from them. David McCall, Senior Editor at BioInsights, speaks with the Chief Technology Officer of Cell Therapy at Tessera Therapeutics, Madhusudan Peshwa, PhD, about his work in addressing these challenges with an RNA gene writing platform combined with a lipid nanoparticle (LNP) delivery system for therapeutic application.

Please enter your email to access content Read now